TG Therapeutics (NASDAQ:TGTX) Stock Rating Reaffirmed by HC Wainwright

TG Therapeutics (NASDAQ:TGTX)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They currently have a $45.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 226.56% from the stock’s current price.

A number of other brokerages have also recently commented on TGTX. StockNews.com cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 24th. The Goldman Sachs Group upped their price target on shares of TG Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Thursday, February 29th. Finally, B. Riley upped their price target on shares of TG Therapeutics from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Monday, February 5th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $29.00.

TG Therapeutics Stock Down 1.5 %

Shares of NASDAQ:TGTX opened at $13.78 on Thursday. The company has a fifty day moving average of $15.11 and a 200-day moving average of $13.91. The company has a market capitalization of $2.13 billion, a PE ratio of 689.34 and a beta of 2.30. The company has a debt-to-equity ratio of 0.62, a quick ratio of 5.18 and a current ratio of 5.92. TG Therapeutics has a 52-week low of $6.46 and a 52-week high of $35.67.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.03. TG Therapeutics had a net margin of 5.42% and a return on equity of 12.89%. The company had revenue of $43.97 million for the quarter, compared to analysts’ expectations of $40.06 million. During the same quarter in the previous year, the firm posted ($0.39) earnings per share. On average, equities analysts predict that TG Therapeutics will post -0.12 EPS for the current fiscal year.

Insider Buying and Selling

In other TG Therapeutics news, Director Laurence N. Charney sold 22,000 shares of the stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total value of $351,340.00. Following the completion of the sale, the director now owns 215,229 shares in the company, valued at approximately $3,437,207.13. The transaction was disclosed in a document filed with the SEC, which is available at this link. 9.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TG Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Pingora Partners LLC purchased a new stake in TG Therapeutics in the 4th quarter valued at about $27,000. PNC Financial Services Group Inc. increased its stake in TG Therapeutics by 131.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,014 shares during the last quarter. Macquarie Group Ltd. increased its stake in TG Therapeutics by 102.3% in the 2nd quarter. Macquarie Group Ltd. now owns 10,190 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 5,152 shares during the last quarter. Coppell Advisory Solutions LLC purchased a new stake in TG Therapeutics in the 2nd quarter valued at about $46,000. Finally, KBC Group NV purchased a new stake in TG Therapeutics in the 4th quarter valued at about $54,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.